Skip to content

Emicizumab

BLOOD AND BLOOD FORMING ORGANS

Also known as: ACE910, emicizumab (genetical recombination), emicizumab-kxwh, hemlibra

EMA approvedFDA approvedPMDA approvedOrphan designationATC B02BX06

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Emicizumab is a drug catalogued in DrugCentral. It was first approved by the FDA in 2017. DrugCentral lists 2 molecular targets, including F9 and F10. Recorded indications include Hereditary factor VIII deficiency disease.

  • Molecular targets: F9 and F10 (2 listed in DrugCentral).
  • Indications: Hereditary factor VIII deficiency disease.
  • ATC code: B02BX06 (Other systemic hemostatics).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

  • Hereditary factor VIII deficiency disease

Mechanism & targets

Molecular targets (2)

TargetGeneActionActivity
Coagulation factor IXF9otherKd 5.80
Coagulation factor XF10otherKd 5.73

Regulatory approvals (3)

DateAgencyMarketed asApplicantOrphan
2018-03-23PMDA—Chugai Pharmaceutical Co., Ltd.
2018-02-23EMA—Roche Registration Limited
2017-11-16FDA—GENENTECH INCYes

ATC classification

ATC codeTherapeutic hierarchy
B02BX06BLOOD AND BLOOD FORMING ORGANS › ANTIHEMORRHAGICS › VITAMIN K AND OTHER HEMOSTATICS › Other systemic hemostatics

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Haemorrhage2871.0
Haemarthrosis2156.3
No adverse event1806.9
Muscle haemorrhage536.8
Traumatic haemorrhage461.0
Off label use358.5
Activated partial thromboplastin time prolonged228.9
Spontaneous haemorrhage205.8
Drug specific antibody present190.1
Anti factor VIII antibody positive189.2
Haematoma181.3
Head injury179.9

Chemical structure

Molecular formula—
Molecular weight—
CAS number1610943-06-0
InChIKey—
PubChem CID—

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Emicizumab used for?

DrugCentral lists the following indications for Emicizumab: Hereditary factor VIII deficiency disease.

How does Emicizumab work?

Its molecular targets in DrugCentral include F9 and F10.

When was Emicizumab first approved?

Emicizumab was first approved by the FDA in 2017.

Browse: all drugs starting with E · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

Status—
First approval2017-11-16
AgencyFDA
Targets2
Indications1
Formula—
DrugCentral ID5268
Interactive profile